BridgeBio Pharma

Latest news

• The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence (opens in a new tab)

  PR Newswire · Oct 1, 2026

• Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 (opens in a new tab)

  Moomoo · Sep 30, 2026

• (BBIO) Movement as an Input in Quant Signal Sets (opens in a new tab)

  Stock Traders Daily · Sep 30, 2026

• Debt to assets ratio of BridgeBio Pharma, Inc. – HAN:2CL (opens in a new tab)

  TradingView · Sep 29, 2026

• BridgeBio Pharma, Inc. Revenue Breakdown – HAN:2CL (opens in a new tab)

  TradingView · Sep 29, 2026

• BridgeBio Pharma (BBIO) Following Acoramidis Study Faces A Wide Fair Value Debate (opens in a new tab)

  Simply Wall Street · Sep 28, 2026

• Real World Heart Study Altering The Investment Case For BridgeBio Pharma Stock? (opens in a new tab)

  Simply Wall Street · Sep 26, 2026

• BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status (opens in a new tab)

  Yahoo Finance · Sep 26, 2026

• BridgeBio Pharma (BBIO) Reports 34% Lower Risk Of Early Clinical Worsening (opens in a new tab)

  Simply Wall Street · Sep 25, 2026

• BridgeBio Pharma (BBIO) Short Interest & Short Float | Updated Sep 2026 (opens in a new tab)

  MarketBeat · Sep 24, 2026

• Why BridgeBio Pharma (BBIO) Stock Is Down Today (opens in a new tab)

  Quiver Quantitative · Sep 23, 2026

• BBIO Looks 56.2% Undervalued on GF Value™ Despite Profitability Challenges (opens in a new tab)

  GuruFocus · Sep 23, 2026

• BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study (opens in a new tab)

  Seeking Alpha · Sep 23, 2026

• BridgeBio Pharma Announces Real-World Study Showing Acoramidis Reduced Clinical Worsening Versus Tafamidis in ATTR-CM (opens in a new tab)

  Quiver Quantitative · Sep 23, 2026

• BridgeBio Pharma (BBIO) Stock Looks Properly Priced For Its Sales Story (opens in a new tab)

  Simply Wall Street · Sep 23, 2026

• BridgeBio Pharma stock finds support near USD 66 (opens in a new tab)

  AD HOC NEWS · Sep 23, 2026

• BridgeBio (NASDAQ: BBIO) CEO’s trust sells 10,000 shares under preset plan (opens in a new tab)

  Stock Titan · Sep 21, 2026

• 7 Red Days In A Row: BridgeBio Pharma Stock Is Down 12% (opens in a new tab)

  Trefis · Sep 21, 2026

• BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares (opens in a new tab)

  Investing.com · Sep 21, 2026

• BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans (opens in a new tab)

  AD HOC NEWS · Sep 19, 2026

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (opens in a new tab)

  The Manila Times · Sep 19, 2026

• Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) (opens in a new tab)

  The Globe and Mail · Sep 11, 2026

• How Achondroplasia NDA Progress Will Impact BridgeBio Pharma Stock (opens in a new tab)

  Simply Wall Street · Sep 11, 2026

• BridgeBio Pharma's drug successes boost valuati... (opens in a new tab)

  Pluang · Sep 10, 2026

• BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com (opens in a new tab)

  Investing.com UK · Sep 10, 2026

• BridgeBio Pharma: Attruby Peak Sales Set To Rise (opens in a new tab)

  Seeking Alpha · Sep 10, 2026

• BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? (opens in a new tab)

  Yahoo Finance · Sep 9, 2026

• BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis? (opens in a new tab)

  Yahoo Finance · Sep 4, 2026

• Lionsbridge takes $704K stake in BridgeBio Pharma as analysts turn bullish (opens in a new tab)

  Dealroom · Sep 2, 2026